Asan Institute for Life Sciences, University of Ulsan College of Medicine, Seoul, South Korea.
Department of Internal Medicine, College of Veterinary Medicine, Chonnam National University, Gwangju, South Korea.
Pediatr Allergy Immunol. 2023 Sep;34(9):e14018. doi: 10.1111/pai.14018.
Broncho-Vaxom (BV) is known to attenuate allergic airway inflammation and chronic bronchitis in humans, but the underlying mechanism of this gut-mediated immunity remains unclear. This study investigated the effects of an oral BV on gut and systemic short-chain fatty acids (SCFAs) and immune responses.
Oral BV was administered daily for 15 days prior to commencing the study in an asthma mouse model. Asthma was induced by ovalbumin (OVA) sensitization followed by a challenge with 1% OVA by inhalation. Asthmatic phenotypes, gut- and systemic- immune responses, and SCFAs in the cecum and blood were then investigated.
Airway hyperresponsiveness, total immunoglobulin E production, and pulmonary inflammation were all significantly suppressed by BV. The interleukin-13 level was also suppressed, whereas TGF-β expression was increased, in the lungs of the BV-treated mice. The regulatory T (Treg) cell numbers were increased in the small intestine, and the acetate level was increased in the cecum and serum after BV treatment. The levels of acetate in the cecum and serum were negatively correlated with airway hyperresponsiveness and with the eosinophil numbers in the BAL fluid of the OVA-induced mice. There was a positive correlation between the acetate levels in the feces and serum and the lung expression of TGF-β in the asthma mice.
Oral BV administration appears to prevent allergic inflammation by enhancing Treg cell proliferation and acetate production in an asthmatic mouse model.
Broncho-Vaxom（BV）已被证实可减轻人类过敏性气道炎症和慢性支气管炎，但这种肠道介导的免疫的潜在机制尚不清楚。本研究旨在探讨口服 BV 对肠道和全身短链脂肪酸（SCFAs）和免疫反应的影响。
在哮喘小鼠模型中，在开始研究之前，每日口服 BV 治疗 15 天。卵清蛋白（OVA）致敏后，通过吸入 1%OVA 诱导哮喘。然后研究哮喘表型、肠道和全身免疫反应以及盲肠和血液中的 SCFAs。
BV 显著抑制气道高反应性、总 IgE 产生和肺部炎症。IL-13 水平也受到抑制，而 TGF-β 的表达在 BV 治疗的小鼠肺部增加。小肠中的调节性 T（Treg）细胞数量增加，盲肠和血清中的乙酸水平在 BV 治疗后增加。盲肠和血清中的乙酸水平与气道高反应性以及 OVA 诱导的小鼠 BAL 液中的嗜酸性粒细胞数量呈负相关。哮喘小鼠粪便和血清中乙酸水平与 TGF-β 在肺部的表达呈正相关。
口服 BV 给药似乎通过增强 Treg 细胞增殖和乙酸产生来预防过敏性炎症在哮喘小鼠模型中。
